Equity Overview
Price & Market Data
Price: $2.07
Daily Change: +$0.01 / 0.48%
Daily Range: $1.99 - $2.17
Market Cap: $12,802,643
Daily Volume: 79,497
Performance Metrics
1 Week: -18.85%
1 Month: -20.68%
3 Months: -19.47%
6 Months: -56.04%
1 Year: -68.79%
YTD: -70.86%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country:
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.